Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pleural Effusion | 24 | 2021 | 74 | 5.760 |
Why?
|
| Pleural Effusion, Malignant | 3 | 2019 | 7 | 1.470 |
Why?
|
| Thoracentesis | 5 | 2020 | 8 | 1.270 |
Why?
|
| Hepatorenal Syndrome | 2 | 2019 | 16 | 1.260 |
Why?
|
| Pleural Diseases | 6 | 2013 | 20 | 1.260 |
Why?
|
| Hemodynamics | 3 | 2021 | 705 | 1.210 |
Why?
|
| Pneumonia | 4 | 2019 | 110 | 1.150 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 115 | 1.140 |
Why?
|
| Echocardiography | 3 | 2019 | 515 | 1.090 |
Why?
|
| Pneumothorax | 7 | 2021 | 42 | 1.080 |
Why?
|
| Pleura | 5 | 2019 | 25 | 1.070 |
Why?
|
| Exudates and Transudates | 6 | 2020 | 25 | 1.040 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 232 | 1.020 |
Why?
|
| Pleurodesis | 4 | 2019 | 11 | 0.960 |
Why?
|
| Ultrasonography, Interventional | 4 | 2021 | 119 | 0.870 |
Why?
|
| Ultrasonography | 5 | 2020 | 453 | 0.870 |
Why?
|
| Pericardial Effusion | 1 | 2021 | 15 | 0.780 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 5 | 2019 | 66 | 0.770 |
Why?
|
| Elasticity | 2 | 2019 | 103 | 0.720 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 710 | 0.680 |
Why?
|
| Liver Cirrhosis | 3 | 2019 | 301 | 0.650 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 232 | 0.640 |
Why?
|
| Lung Diseases | 3 | 2017 | 175 | 0.630 |
Why?
|
| Empyema, Pleural | 2 | 2014 | 13 | 0.620 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.620 |
Why?
|
| Indoles | 4 | 2018 | 146 | 0.600 |
Why?
|
| Pneumoperitoneum | 1 | 2016 | 7 | 0.570 |
Why?
|
| Aged | 27 | 2022 | 14842 | 0.560 |
Why?
|
| Drainage | 5 | 2022 | 133 | 0.560 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2016 | 161 | 0.540 |
Why?
|
| Humans | 51 | 2022 | 68525 | 0.510 |
Why?
|
| Paracentesis | 5 | 2016 | 25 | 0.480 |
Why?
|
| Hypertension | 3 | 2022 | 1531 | 0.450 |
Why?
|
| Intensive Care Units | 1 | 2014 | 344 | 0.420 |
Why?
|
| Lung | 6 | 2022 | 849 | 0.420 |
Why?
|
| Diagnostic Errors | 2 | 2019 | 100 | 0.410 |
Why?
|
| Chylothorax | 1 | 2011 | 11 | 0.390 |
Why?
|
| Male | 31 | 2022 | 37281 | 0.390 |
Why?
|
| Middle Aged | 25 | 2021 | 21119 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2021 | 331 | 0.390 |
Why?
|
| Dyspnea | 5 | 2019 | 87 | 0.380 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2021 | 110 | 0.380 |
Why?
|
| Female | 31 | 2021 | 38015 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 529 | 0.360 |
Why?
|
| Manometry | 6 | 2019 | 276 | 0.360 |
Why?
|
| Cholesterol | 1 | 2011 | 331 | 0.350 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 99 | 0.320 |
Why?
|
| Adult | 15 | 2021 | 21375 | 0.290 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2006 | 17 | 0.290 |
Why?
|
| Postoperative Complications | 4 | 2022 | 1615 | 0.270 |
Why?
|
| Catheters, Indwelling | 2 | 2019 | 72 | 0.270 |
Why?
|
| Pleurisy | 3 | 2017 | 8 | 0.260 |
Why?
|
| Eucalyptus | 1 | 2004 | 3 | 0.260 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2004 | 6 | 0.260 |
Why?
|
| Laryngitis | 1 | 2004 | 12 | 0.250 |
Why?
|
| Retrospective Studies | 8 | 2021 | 7264 | 0.250 |
Why?
|
| Irritants | 1 | 2004 | 10 | 0.250 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1465 | 0.240 |
Why?
|
| Respiratory Tract Fistula | 1 | 2003 | 2 | 0.240 |
Why?
|
| Dura Mater | 1 | 2003 | 23 | 0.230 |
Why?
|
| Chest Tubes | 2 | 2017 | 18 | 0.230 |
Why?
|
| Spinal Cord Diseases | 1 | 2003 | 23 | 0.230 |
Why?
|
| Vital Capacity | 3 | 2018 | 43 | 0.230 |
Why?
|
| Aged, 80 and over | 9 | 2022 | 4843 | 0.220 |
Why?
|
| Transferrin | 1 | 2003 | 94 | 0.220 |
Why?
|
| Pulmonary Edema | 2 | 2019 | 37 | 0.220 |
Why?
|
| Prospective Studies | 5 | 2022 | 3702 | 0.210 |
Why?
|
| Placebos | 2 | 2019 | 195 | 0.210 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1139 | 0.210 |
Why?
|
| Pneumonectomy | 1 | 2022 | 79 | 0.200 |
Why?
|
| Thoracostomy | 2 | 2014 | 6 | 0.200 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 207 | 0.200 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 12 | 0.200 |
Why?
|
| Asthma | 1 | 2004 | 345 | 0.190 |
Why?
|
| Proteins | 4 | 2014 | 473 | 0.190 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 190 | 0.180 |
Why?
|
| Lung Neoplasms | 4 | 2011 | 1172 | 0.180 |
Why?
|
| Suction | 1 | 2019 | 33 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2323 | 0.180 |
Why?
|
| Critical Illness | 1 | 2021 | 191 | 0.180 |
Why?
|
| Eligibility Determination | 1 | 2019 | 31 | 0.180 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 39 | 0.180 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 114 | 0.170 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 41 | 0.170 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 201 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 60 | 0.170 |
Why?
|
| Chest Pain | 1 | 2019 | 151 | 0.170 |
Why?
|
| Safety | 1 | 2019 | 145 | 0.170 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.160 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 419 | 0.160 |
Why?
|
| Disease Progression | 5 | 2019 | 1037 | 0.160 |
Why?
|
| Urinoma | 1 | 2017 | 2 | 0.150 |
Why?
|
| Hydronephrosis | 1 | 2017 | 12 | 0.150 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 157 | 0.150 |
Why?
|
| Scleroderma, Systemic | 1 | 2021 | 446 | 0.150 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2016 | 4 | 0.140 |
Why?
|
| Duodenal Ulcer | 1 | 2016 | 16 | 0.140 |
Why?
|
| Likelihood Functions | 1 | 2016 | 105 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 239 | 0.140 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 29 | 0.140 |
Why?
|
| Delirium | 1 | 2016 | 45 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 1341 | 0.130 |
Why?
|
| Yellow Nail Syndrome | 1 | 2014 | 1 | 0.130 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2014 | 3 | 0.130 |
Why?
|
| Bronchoscopy | 2 | 2014 | 147 | 0.130 |
Why?
|
| Thoracoscopy | 1 | 2014 | 6 | 0.130 |
Why?
|
| Radiography | 1 | 2016 | 572 | 0.130 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2013 | 67 | 0.130 |
Why?
|
| Pulmonary Medicine | 1 | 2014 | 31 | 0.120 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 27 | 0.120 |
Why?
|
| Heart Failure | 2 | 2014 | 1179 | 0.120 |
Why?
|
| Hydro-Lyases | 1 | 2014 | 4 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2264 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 74 | 0.120 |
Why?
|
| Tuberculosis, Pleural | 1 | 2013 | 2 | 0.120 |
Why?
|
| Parasitic Diseases | 1 | 2013 | 9 | 0.120 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2013 | 2 | 0.120 |
Why?
|
| Vasculitis | 1 | 2013 | 33 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3256 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 659 | 0.110 |
Why?
|
| Capillaries | 1 | 2013 | 105 | 0.110 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 514 | 0.100 |
Why?
|
| Deoxyribonucleases | 1 | 2011 | 8 | 0.100 |
Why?
|
| Sclerosing Solutions | 1 | 2011 | 6 | 0.100 |
Why?
|
| Superantigens | 1 | 2011 | 7 | 0.100 |
Why?
|
| Streptokinase | 1 | 2011 | 23 | 0.100 |
Why?
|
| Chylomicrons | 1 | 2011 | 6 | 0.100 |
Why?
|
| Hydrothorax | 1 | 2011 | 7 | 0.100 |
Why?
|
| Thoracic Duct | 1 | 2011 | 6 | 0.100 |
Why?
|
| Ascites | 1 | 2011 | 38 | 0.100 |
Why?
|
| Triglycerides | 1 | 2011 | 184 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2013 | 434 | 0.090 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2021 | 20 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 365 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2011 | 258 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 696 | 0.090 |
Why?
|
| Endosonography | 2 | 2011 | 177 | 0.090 |
Why?
|
| Thiazoles | 1 | 2009 | 95 | 0.090 |
Why?
|
| Respiratory Function Tests | 2 | 2019 | 123 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 799 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2019 | 249 | 0.080 |
Why?
|
| Pressure | 2 | 2006 | 252 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2009 | 178 | 0.080 |
Why?
|
| Brachial Plexus Neuritis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Phrenic Nerve | 1 | 2008 | 4 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 300 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 377 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 37 | 0.080 |
Why?
|
| Paralysis | 1 | 2008 | 35 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2022 | 7028 | 0.080 |
Why?
|
| Pneumothorax, Artificial | 1 | 2006 | 2 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2013 | 618 | 0.070 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2006 | 9 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2006 | 52 | 0.070 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2006 | 69 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 76 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2006 | 169 | 0.070 |
Why?
|
| Models, Animal | 1 | 2006 | 252 | 0.070 |
Why?
|
| Lung Transplantation | 1 | 2006 | 88 | 0.060 |
Why?
|
| Asbestosis | 1 | 2004 | 3 | 0.060 |
Why?
|
| Uremia | 1 | 2004 | 10 | 0.060 |
Why?
|
| Hemothorax | 1 | 2004 | 9 | 0.060 |
Why?
|
| Bronchial Provocation Tests | 1 | 2004 | 9 | 0.060 |
Why?
|
| Skin Tests | 1 | 2004 | 30 | 0.060 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.060 |
Why?
|
| Respiratory Sounds | 1 | 2004 | 35 | 0.060 |
Why?
|
| Spirometry | 1 | 2004 | 47 | 0.060 |
Why?
|
| Rheumatic Diseases | 1 | 2004 | 35 | 0.060 |
Why?
|
| Vocal Cords | 1 | 2004 | 18 | 0.060 |
Why?
|
| Plant Leaves | 1 | 2004 | 49 | 0.060 |
Why?
|
| Methysergide | 1 | 2004 | 4 | 0.060 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2004 | 3 | 0.060 |
Why?
|
| Nitrofurantoin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Penicillamine | 1 | 2004 | 10 | 0.060 |
Why?
|
| Immunoglobulin E | 1 | 2004 | 91 | 0.060 |
Why?
|
| Odorants | 1 | 2004 | 52 | 0.060 |
Why?
|
| Laryngoscopy | 1 | 2004 | 61 | 0.060 |
Why?
|
| Serotonin Antagonists | 1 | 2004 | 31 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 648 | 0.060 |
Why?
|
| Clozapine | 1 | 2004 | 46 | 0.060 |
Why?
|
| Bleomycin | 1 | 2004 | 67 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2004 | 77 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 77 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2004 | 47 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 129 | 0.060 |
Why?
|
| Methotrexate | 1 | 2004 | 91 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 323 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 218 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2004 | 133 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2004 | 82 | 0.060 |
Why?
|
| Fibrosis | 1 | 2004 | 371 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2022 | 24 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5719 | 0.050 |
Why?
|
| Androgens | 1 | 2022 | 40 | 0.050 |
Why?
|
| Prevalence | 1 | 2006 | 1609 | 0.050 |
Why?
|
| Glucose | 2 | 2013 | 307 | 0.050 |
Why?
|
| Neutrophils | 2 | 2013 | 204 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 186 | 0.050 |
Why?
|
| Oxygen | 1 | 2022 | 386 | 0.050 |
Why?
|
| Gravitation | 1 | 2019 | 12 | 0.050 |
Why?
|
| Pain, Procedural | 1 | 2019 | 4 | 0.050 |
Why?
|
| Operative Time | 1 | 2019 | 45 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 384 | 0.040 |
Why?
|
| Oximetry | 1 | 2018 | 29 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2018 | 87 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 76 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 74 | 0.040 |
Why?
|
| Young Adult | 3 | 2014 | 5708 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1548 | 0.040 |
Why?
|
| New York | 1 | 2017 | 223 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1582 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2356 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2019 | 276 | 0.040 |
Why?
|
| Diarrhea | 1 | 2016 | 63 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 977 | 0.030 |
Why?
|
| Phenotype | 1 | 2018 | 946 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2014 | 7 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1030 | 0.030 |
Why?
|
| Adolescent | 3 | 2014 | 8903 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1425 | 0.030 |
Why?
|
| Albumins | 1 | 2014 | 72 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 20877 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 807 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 248 | 0.030 |
Why?
|
| Education, Medical | 1 | 2014 | 147 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 244 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 306 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2013 | 228 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 2004 | 0.030 |
Why?
|
| Kidney | 1 | 2017 | 945 | 0.030 |
Why?
|
| Biopsy | 1 | 2013 | 539 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2011 | 94 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 242 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 705 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 191 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 104 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 274 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 160 | 0.020 |
Why?
|
| South Carolina | 1 | 2017 | 2750 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 369 | 0.020 |
Why?
|
| Dasatinib | 1 | 2009 | 17 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 63 | 0.020 |
Why?
|
| United States | 1 | 2022 | 7335 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 647 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2014 | 657 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1753 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 880 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2077 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2014 | 2453 | 0.020 |
Why?
|
| Diaphragmatic Eventration | 1 | 2008 | 9 | 0.020 |
Why?
|
| Arm | 1 | 2008 | 59 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 2891 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 1593 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3185 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1419 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2006 | 36 | 0.020 |
Why?
|
| Fistula | 1 | 2006 | 29 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2007 | 172 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2006 | 368 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 291 | 0.020 |
Why?
|
| Pain | 1 | 2008 | 472 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2006 | 384 | 0.010 |
Why?
|
| Child | 1 | 2014 | 6400 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2798 | 0.010 |
Why?
|